ClinicalTrials.gg
CompletedNCT04649645SMILEUpdated Sep 8, 2025

Changes in Oral Health in Tobacco Cigarettes Smokers After Switching to Combustion-Free Nicotine Delivery Systems

An interventional study of TOBACCO CIGARETTES and COMBUSTION-FREE NICOTINE DELIVERY SYSTEMS (C-F NDS) in Gingivitis and Periodontal Diseases, sponsored by Eclat Srl.. Completed at 1 site in Italy. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-08.

Sponsored by Eclat Srl. · Not applicable, Interventional, and Screening

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
460
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies in Gingivitis with a site in Italy — 9 open to participants now, 10 under way, 1 of them phase 3. Gingivitis · Italy.

Enrollment
Largest of 28
460 · median 55
Started
2021
with 2 others
No phase
22 of 32
5 open now
Registered
12th of 32
by date
Lead sponsor
1 of 32
Eclat Srl.

Among the 32 studies in Gingivitis with a site in Italy, this one has the largest enrollment of the 28 interventional ones that give a count, is one of 3 that started in 2021, is one of 22 with no phase, and was the 12th registered.

Gingivitis

636 studies on the registry are indexed under Gingivitis; 109 are open to participants now.

Browse Gingivitis studies →

Open to participants now

9 of the 32 studies in Gingivitis with a site in Italy are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 54 Gingivitis studies recruiting now, 16 (30%) set no upper age limit and 36 (67%) stop at 75 or younger; 11 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Gingivitis with a site in Italy, or all of them as a file.
02

Study summary

Although the well-known detrimental effects of conventional cigarette smoking on oral health, there are still lack of evidences about the impact of less harmful alternatives (such as electronic cigarettes or heat not burn products), especially in young smokers with clinical absence of signs of moderate to severe periodontitis.

This study aims to investigate whether cigarette smokers who switch to combustion-free nicotine delivery systems (C-F NDS) undergo measurable improvements in oral health parameters and teeth appearance, comparing short- and long-term impact on periodontal health between smokers continuing with conventional cigarette smoking, those switching to combustion-free nicotine delivery systems (C-F NDS), and never-smokers.

The investigator propose a prospective, multicenter, interventional, open label, randomized, controlled, three parallel-arms study assessing oral health parameters and teeth appearance of 18 months duration.

Read the detailed description

SMILE is an international, open label, randomized, controlled study of 18 months duration designed to assess whether cigarette smokers switching to combustion free-nicotine delivery systems (C-F NDS) will undergo measurable improvements in oral health parameters and teeth appearance as a consequence of avoiding exposure to cigarette smoke. Five countries have so far agreed to participate: Italy, Moldova, Poland, UK and Indonesia. An amendment will be submitted to the REC once the final two countries are signed up.

A volunteer population of never-smokers and regular smokers of conventional cigarettes with a clinical absence of signs of periodontitis will be recruited. Regular cigarette smokers will be randomized 1:4 ratio either continuing to smoke commercially manufactured conventional cigarettes (Study Arm A) or switching to C-F NDS (Study Arm B). Never Smokers will be assigned to Arm C.The intended minimum number of participants by the end of the study is 460.

Before randomization, all smokers will be reminded of the risks associated with smoking and will be offered a free smoking cessation program according to standard local guidelines and depending on the local availability of antismoking services. Those who decline the invitation will be eligible for recruitment into the study.

Smokers are free to voluntarily quit smoking/C-F NDS and/or withdraw from the study at any time.

Duration:

All participants will attend a total of seven clinics visits: Day -28 to Day -1 - Screening; Day 0 - Enrollment and Randomization (Visit 0); Day 14 (+/-3 days) - Baseline Visit (Visit 1); Day 90 (+/-5 days) - Visit 2; Day 180 (+/-7 days) - Visit 3; Day 360 (+/-10 days) - Visit 4; Day 540 (+/-10 days) - Visit 5.

Each participant will undergo screening within 28 days prior to Visit 0. Eligible participants will be enrolled and randomized on Visit 0. Baseline assessments will be performed at Visit 1, 14 days after Visit 0. The overall duration of study participation for each participant will be a maximum of 568 +/- 10 days.

The randomization sequence will be computer generated, with an allocation ratio of 1:4 (Study Arm A : Study Arm B; Smokers : N-C NDS users) to compensate for an estimated 25% success rate (combined smoking abstinence rate + >90% smoking reduction rate) in the long term. The randomization scheme will be provided to clinical sites via a web-based application set up by the CRO. The staff randomizing the participant will access the web-based application when the participant is with them, entering their participant identification number, date of birth and initials into the program. The allocation will be immediately provided by the program/software.

Product use Regular smokers will continue to smoke their usual brand of conventional cigarette until Baseline on Visit 1. After Visit 1, participants on both Arms A and B will be asked to use only their assigned products ad libitum for the whole duration of the study.

Participants in Arm A will continue smoking their own conventional cigarette brand, as usual.

Participants in Arm B will have the option to try and choose among a selection of either three e-liquids or three tobacco sticks (depending on the C-F NDS they have chosen). They will also be trained and instructed on how to correctly use their chosen C-F NDS. Participants wishing to use a heated tobacco device (HTD) will receive the number of tobacco sticks per day corresponding to the number of cigarettes smoked per day at baseline. Participants wishing to use a vaping product will receive one vaping kit and supply of e-liquids of their choice enough to provide consumption in between supply visits (see Table 2); on average they will receive 4 x 10 ml refill containers per week. Free products will be supplied at each subsequent visit throughout the whole duration of the study.

Participants in Arm C will continue to not smoking or use any form of tobacco or nicotine-containing products.

A prospective monitoring of cigarette consumption, C-F NDS use, and oral hygiene routine will be carried out throughout the study with the tracker APP. Moreover, participants in Arm B will be asked to return all empty, part-used, and unused consumables (tobacco sticks, e-cigarette cartridges, e-liquid refill bottles) at each study visit.

Justification for Study Design

Participants in this study will be a minimum of 18 years of age. This is based on:

  • The legal age to obtain tobacco products is 18 years
  • The presence of at least 10 natural anterior permanent teeth in total (cuspid to cuspid, lower and upper jaw).

To investigate the effects of abstaining from smoking by switching in smokers with clinical absence of periodontitis, a population of both smokers who are intending to make the switch to N-C NDS and never-smokers will be recruited. By the end of the study, it is estimated that a high proportion (approx. 75%) of patients randomized in the Arm B of the study will not be able to achieve success (defined as either complete smoking abstinence or as at least 90% smoking reduction). To account for this, the C-F NDS population will be over sampled and a 1:4 randomization ratio scheme (i.e. for every patient randomized in the continue-to-smoke population, four will be randomized in the C-F NDS population) will be adopted.

It will not be possible to blind participants to the intervention they will be receiving. It will not be possible to blind trial staff when providing the interventions and collecting data. However, data analyses will be conducted blind to Study Arms allocation. All other trial staff who have access to outcome data will remain blinded until prespecified data analyses will be completed.

03

Conditions studied

  • Gingivitis
  • Periodontal Diseases

Keywords

  • Electronic cigarettes
  • Tobacco Harm Reduction
  • Heated tobacco products
  • Smokers
  • Gingivitis
  • Modified gingival index
  • Oral Health
  • Tooth stain
  • Periodontitis
  • Dental plaque imaging
  • Dental discoloration
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Demonstrate understanding of the study and willingness to participate in the study by providing a signed written
  • Healthy subjects, not taking regular medications for chronic medical conditions
  • Adults, age at least 18 years old.
  • Presence of at least 10 natural anterior teeth in total (cuspid to cuspid, lower and upper jaw).
  • Presence of at least 18 'scorable' teeth with scorable facial and lingual surfaces. Teeth that are grossly carious, orthodontically banded, exhibiting general cervical abrasion and/or enamel abrasion, and third molars will not be included in the tooth count;
  • Willingness and ability to comply with the requirements of the study including installing an APP on their digital device, e.g. smart phone or tablet.

For Arms A and B, subject have to be:

  • Regular smokers, defined as:

    • Smoked for at least five consecutive years prior to Screening.
    • Smoked >10 and \< 30 cigarettes per day (CPD).
    • with an exhaled breath carbon monoxide (CO) level ≥7 ppm at Screening.
  • willing to regularly use of any nicotine or tobacco product other than their own conventional cigarettes brand within 14 days prior to Screening.
  • willing to change to use of study products or if randomized to Arm A continuing to use their own brand of conventional cigarettes for the whole duration of the study.

For Arm C, subjects have to be:

  • Never-smokers, defined as:

    • never smoked or who have smoked \< 100 cigarettes in their lifetime and none in the 30 days prior to screening.
    • with an exhaled breath CO level \< 7 ppm at screening.
  • willing to not smoke or use any form of tobacco or nicotine-containing products for the whole duration of the study.

Exclusion criteria

Exclusion Criteria:

  • Pregnancy.
  • Presence of extensive crown or bridge work, dental implants, and/or rampant decay (per Investigator/Examiner discretion)
  • Significant oral soft tissue pathology or any type of gingival overgrowth, other than plaque-induced gingivitis and mild periodontitis (Stage I)
  • Moderate to Severe Periodontitis (Stage II, III and IV) based on 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions, which require:

    • Detectable Interdental Clinical Attachment Loss (CAL) ≥ 3 mm at ≥ 2 non-adjacent teeth.
    • Buccal or Oral CAL ≥3 mm with pocketing ≥ 5 mm detectable at ≥ 2 teeth.
  • Removable dentures or fixed and removable orthodontic appliance (except fixed lingual wires).
  • Significant history of alcoholism or drug abuse (other than tobacco/nicotine) within 24 months prior to screening, as determined by the Investigator.
  • A course of treatment with any medications or substances (other than tobacco/nicotine) which:

    • interfere with the cyclooxygenase pathway (e.g. anti-inflammatory drugs including aspirin and ibuprofen) within 3 days prior to each visit.
    • are known to have antibacterial activity (e.g. antibiotics) within 7 days prior to each visit.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
460 participants (actual)

Study arms

  • Active comparator
    Standard Arm (Arm A)

    Participant continues smoking their own cigarette brand.

    Other: TOBACCO CIGARETTES

  • Active comparator
    Intervention Arm (Arm B)

    Participant switches to using C-F NDS.

    Other: COMBUSTION-FREE NICOTINE DELIVERY SYSTEMS (C-F NDS)

  • Active comparator
    Control Arm (Arm C)

    Participant continues to not smoking or using of any nicotine/tobacco products.

    Other: NOT SMOKING

Interventions

  • OtherTOBACCO CIGARETTES

    Participants in Arm A will continue smoking their own cigarette brand as usual.

  • OtherCOMBUSTION-FREE NICOTINE DELIVERY SYSTEMS (C-F NDS)

    Participants in Arm B will trial and familiarize with a selection of C-F NDS in order to choose the product of their preference. They will be trained and counselled on the chosen C-F NDS. Prior to check-out, participants wishing to use a heated tobacco device will receive one kit and a full 2 weeks supply of tobacco sticks of their choice (they will receive a number of tobacco sticks per day corresponding to the number of cigarettes smoked at baseline); those wishing to use a vaping product will receive one vaping kit and a full 2 weeks supply of e-liquids of their choice (they will receive twelve 10 ml refill containers).

  • OtherNOT SMOKING

    Participants in Arm C will continue not smoking or use any form of tobacco or nicotine-containing products.

06

What researchers measure

Primary outcomes

  1. Modified Gingival Index (MGI)

    Percentage (%) mean changes in MGI from baseline at different study time-points

    Time frame: Changes in the severity of gingivitis from baseline will be assessed at 3 months, 6 months, 12 months and 18 months

Secondary outcomes

  1. Macpherson Modification of Lobene Tooth Stain Index (MLSI)

    Change in MLSI from baseline at different study time-points

    Time frame: Changes in extent and severity of tooth stains from baseline will be assessed at 3 months, 6 months, 12 months and 18 months

  2. Dental Discolorations

    Percentage (%) mean change in dental shade (L, a\*, b\*) from baseline at different study time-points

    Time frame: Changes in dental discolouration from baseline will be assessed at 3 months, 6 months, 12 months and 18 months

  3. Plaque Score Imaging (QLF)

    Changes in ΔR30 and ΔR120 from baseline at different study time-points

    Time frame: Changes in dental plaque from baseline will be assessed at 3 months, 6 months, 12 months and 18 months

  4. Oral Health Quality of Life (OHQOL)

    Changes in OHQOL from baseline at different study time-points

    Time frame: Changes in OHQOL score from baseline will be assessed at 3 months, 6 months, 12 months and 18 months

  5. EuroQoL Visual Analog Scale (EQ VAS - QoL)

    Changes in EQ VAS-QoL from baseline at different study time-points

    Time frame: Changes in the EQ VAS - QoL score from baseline will be assessed at 3 months, 6 months, 12 months and 18 months

07

Study locations

1 site
  • Addendo srl
    Catania, Catania 95100, Italy
08

References and documents

Publications

  • Offenbacher S. Periodontal diseases: pathogenesis. Ann Periodontol. 1996 Nov;1(1):821-78. doi: 10.1902/annals.1996.1.1.821. No abstract available. PubMed 9118282 ↗
  • Research, Science and Therapy Committee. Position Paper: Diagnosis of Periodontal Diseases. J Periodontol. 2003 Aug;74(8):1237-1247. doi: 10.1902/jop.2003.74.8.1237. PubMed 29539063 ↗
  • Armitage GC. Clinical evaluation of periodontal diseases. Periodontol 2000. 1995 Feb;7:39-53. doi: 10.1111/j.1600-0757.1995.tb00035.x. No abstract available. PubMed 9567929 ↗
  • Czesnikiewicz-Guzik M, D'Aiuto F, Deanfield JE. Understanding residual inflammatory risk sheds new light on the clinical importance of periodontitis in cardiovascular disease. Eur Heart J. 2020 Feb 14;41(7):818-819. doi: 10.1093/eurheartj/ehaa107. No abstract available. PubMed 32058578 ↗
  • Armitage GC. Periodontal infections and cardiovascular disease--how strong is the association? Oral Dis. 2000 Nov;6(6):335-50. doi: 10.1111/j.1601-0825.2000.tb00126.x. PubMed 11355266 ↗
  • Bergstrom J. Cigarette smoking as risk factor in chronic periodontal disease. Community Dent Oral Epidemiol. 1989 Oct;17(5):245-7. doi: 10.1111/j.1600-0528.1989.tb00626.x. PubMed 2791514 ↗
  • Bergstrom J, Preber H. Tobacco Use as a Risk Factor. J Periodontol. 1994 May;65(5):545-550. doi: 10.1902/jop.1994.65.5.545. PubMed 29539746 ↗
  • Haber J. Smoking is a major risk factor for periodontitis. Curr Opin Periodontol. 1994:12-8. PubMed 8032453 ↗
  • Bergstrom J. Tobacco smoking and chronic destructive periodontal disease. Odontology. 2004 Sep;92(1):1-8. doi: 10.1007/s10266-004-0043-4. PubMed 15490298 ↗
  • Ueno M, Ohara S, Sawada N, Inoue M, Tsugane S, Kawaguchi Y. The association of active and secondhand smoking with oral health in adults: Japan public health center-based study. Tob Induc Dis. 2015 Jul 29;13(1):19. doi: 10.1186/s12971-015-0047-6. eCollection 2015. PubMed 26225132 ↗
  • Eriksen HM, Nordbo H. Extrinsic discoloration of teeth. J Clin Periodontol. 1978 Nov;5(4):229-36. doi: 10.1111/j.1600-051x.1978.tb01916.x. PubMed 363748 ↗
  • Christen AG. The impact of tobacco use and cessation on oral and dental diseases and conditions. Am J Med. 1992 Jul 15;93(1A):25S-31S. doi: 10.1016/0002-9343(92)90624-k. PubMed 1497000 ↗
  • Zhu S, Melcer T, Sun J, Rosbrook B, Pierce JP. Smoking cessation with and without assistance: a population-based analysis. Am J Prev Med. 2000 May;18(4):305-11. doi: 10.1016/s0749-3797(00)00124-0. PubMed 10788733 ↗
  • West R, Zhou X. Is nicotine replacement therapy for smoking cessation effective in the "real world"? Findings from a prospective multinational cohort study. Thorax. 2007 Nov;62(11):998-1002. doi: 10.1136/thx.2007.078758. Epub 2007 Jun 15. PubMed 17573444 ↗
  • Polosa R, Farsalinos K, Prisco D. Health impact of electronic cigarettes and heated tobacco systems. Intern Emerg Med. 2019 Sep;14(6):817-820. doi: 10.1007/s11739-019-02167-4. Epub 2019 Aug 14. No abstract available. PubMed 31414334 ↗
  • Polosa R, Rodu B, Caponnetto P, Maglia M, Raciti C. A fresh look at tobacco harm reduction: the case for the electronic cigarette. Harm Reduct J. 2013 Oct 4;10:19. doi: 10.1186/1477-7517-10-19. PubMed 24090432 ↗
  • Farsalinos KE, Polosa R. Safety evaluation and risk assessment of electronic cigarettes as tobacco cigarette substitutes: a systematic review. Ther Adv Drug Saf. 2014 Apr;5(2):67-86. doi: 10.1177/2042098614524430. PubMed 25083263 ↗
  • McNeill A, Brose L S, Calder R, Bauld L and Robson D. Evidence review of e-cigarettes and heated tobacco products 2018. A report commissioned by Public Health England.
  • Papapanou PN, Sanz M, Buduneli N, Dietrich T, Feres M, Fine DH, Flemmig TF, Garcia R, Giannobile WV, Graziani F, Greenwell H, Herrera D, Kao RT, Kebschull M, Kinane DF, Kirkwood KL, Kocher T, Kornman KS, Kumar PS, Loos BG, Machtei E, Meng H, Mombelli A, Needleman I, Offenbacher S, Seymour GJ, Teles R, Tonetti MS. Periodontitis: Consensus report of workgroup 2 of the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions. J Periodontol. 2018 Jun;89 Suppl 1:S173-S182. doi: 10.1002/JPER.17-0721. PubMed 29926951 ↗
  • Lobene RR, Weatherford T, Ross NM, Lamm RA, Menaker L. A modified gingival index for use in clinical trials. Clin Prev Dent. 1986 Jan-Feb;8(1):3-6. No abstract available. PubMed 3485495 ↗
  • Conte G, Pacino SA, Urso S, Greiling D, Caponnetto P, Pedulla E, Generali L, Consolo U, Checchi V, Gospodaru S, Bordeniuc G, Fala V, Kowalski J, Nowak M, Gorska R, Amaliya A, Chapple I, Milward M, Maclure R, Nardi GM, Polosa R. Changes in Oral Health and Dental Esthetic in Smokers Switching to Combustion-Free Nicotine Alternatives: Protocol for a Multicenter and Prospective Randomized Controlled Trial. JMIR Res Protoc. 2024 Feb 23;13:e53222. doi: 10.2196/53222. PubMed 38393754 ↗
  • Conte G, Amaliya A, Gupta S, Emma R, Gospodaru S, Bordeniuc G, Fala V, Pacino SA, Urso S, Zucchelli G, Polosa R. Repeatability of dental plaque quantitation by light induced fluorescence technology in current, former, and never smokers. BMC Oral Health. 2023 Jul 13;23(1):480. doi: 10.1186/s12903-023-03154-0. PubMed 37443061 ↗
  • Conte G, Pacino SA, Urso S, Emma R, Pedulla E, Cibella F, Stefanini M, Zucchelli G, Polosa R. Repeatability of dental shade by digital spectrophotometry in current, former, and never smokers. Odontology. 2022 Jul;110(3):605-618. doi: 10.1007/s10266-022-00692-x. Epub 2022 Mar 10. PubMed 35266059 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2021 to primary completion in Dec 2024, 38 months.

Of 207 non-industry interventional studies with no phase under Gingivitis, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 17. This study's 38 months is above that.

Counting every sponsor, half of 260 studies reached it within 7 months; a quarter within 3 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 25, 2020
First posted
Dec 2, 2020
StartActual
Oct 18, 2021
Primary completionActual
Dec 19, 2024
CompletionActual
Dec 19, 2024
Last update
Sep 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04649645
Lead sponsor
Eclat Srl.
Collaborators
University of Catania
Responsible party
Sponsor
First posted
Dec 2, 2020
Start date
Oct 18, 2021
Primary completion
Dec 19, 2024
Completion
Dec 19, 2024
Last update
Sep 8, 2025

Study contacts

Antonio Pacino, D.D.S.
principal investigator · Addendo srl, Catania, Italy

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion